Related Experiment Video

Updated: Aug 14, 2025

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

1.8K

Liver cancer cells as the model for developing liver-targeted RNAi therapeutics

Beibei Hou1, Linhui Qin1, Linfeng Huang2

  • 1Wang-Cai Biochemistry Lab, Division of Natural and Applied Sciences, Duke Kunshan University, Kunshan, Jiangsu, China.

Biochemical and Biophysical Research Communications
|January 14, 2023
PubMed

Insights

RNA interference (RNAi) therapeutics show promise for metabolic liver diseases. This study identifies liver cancer cell lines as effective models for developing and testing these precision medicines, particularly for siRNA delivery.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • RNA interference (RNAi) is a gene regulation mechanism utilizing small interfering RNAs (siRNAs).
  • RNAi therapeutics offer potential for treating liver-associated metabolic diseases.
  • Developing effective cell models is crucial for advancing liver-targeted RNAi therapeutics.

Purpose of the Study:

  • To survey liver cancer cell lines for key genes in RNAi therapeutics.
  • To assess the utility of these cell lines for studying siRNA delivery and gene function.
  • To establish a convenient model for identifying and testing siRNA drug candidates.

Main Methods:

  • Expression profiling of ASGR and metabolic disease genes (PCSK9, ANGPTL3, CIDEB, LDLR) in liver cancer cell lines.
  • High-content screening using lipid droplet staining to confirm gene involvement in lipid metabolism.
  • Utilizing an EGFP reporter system to evaluate gene knockdown efficiency of GalNAc-siRNA.

Main Results:

  • Several liver cancer cell lines express high levels of ASGR1, essential for GalNAc-siRNA uptake.
  • PCSK9, ANGPTL3, and CIDEB were confirmed to be involved in lipid metabolism.
  • Hep G2 cells demonstrated efficacy in evaluating GalNAc-siRNA knockdown efficiency.

Conclusions:

  • Liver cancer cell lines can serve as valuable models for RNAi therapeutic development.
  • These models facilitate the study of ASGR-mediated siRNA delivery and gene function in liver cells.
  • The findings support the use of these cell lines for identifying and testing novel siRNA drug candidates for liver diseases.
Keywords:
ANGPTL3ASGRCIDEBGalNAcHepatocellular carcinomaPCSK9RNAisiRNA

More Related Videos

Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins and mRNA into Freshly Isolated Primary Mouse Hepatocytes09:45

Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins and mRNA into Freshly Isolated Primary Mouse Hepatocytes

Published on: June 2, 2022

2.8K
A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth08:15

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Published on: February 2, 2024

917

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K